DEXCOM INC — Director's Dealing 2022

Mar 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-03-08

Reporting Person: Leach Jacob Steven (EVP Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-08	Common Stock	A	6741	$0.001	Acquired	79019	Direct
2022-03-09	Common Stock	D	1317	$406.0567	Disposed	77702	Direct
2022-03-09	Common Stock	D	2065	$406.0567	Disposed	75637	Direct
2022-03-09	Common Stock	D	891	$406.0567	Disposed	74746	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	11824	Indirect

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2: Included in this number are 18,362 unvested restricted stock units, 6,741 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 4,780 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 3,916 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4: Shares are held by the Gregg Family Grandchildren's Trust UAD 12/30/2010, with respect to which the reporting person's spouse is a trustee.